Phase 1 HIV mosaic vaccine study launched at Oxford university
Simon Collins, HIV i-Base
On 5 July 2021, researchers at Oxford University published a press release for the launch of a phase 1 study of an HIV vaccine.
The HIV-CORE 0052 study will enroll 13 HIV negative participants who are not at high risk of catching HIV.
It will use a mosaic vaccine called HIVconsvX that targets different sections of the virus. The vaccines will use two doses, four weeks apart.
Phase 1 studies look for whether the experimental vaccine is safe and whether it generates immune responses. This study will not produce results on whether the vaccine is effective.
Results are expected by April 2022.
The study is funded by the EU as part of the European Aids Vaccine Initiative (EAVI2020). Similar studies are planned in other countries, including in Europe, Africa and the US.
Oxford University press release. HIV vaccine trial starts at Oxford. (5 July 2021).
This article was first published on 7 July 2021.